CAR-T cells: Beyond CD19

CAR-T cells are a new and exciting drug class in which treatment involves the use of transformed immune cells for cancer therapy. A patient’s T- cells are removed, transduced and expanded…

0 Comments

Biosimilars on the Sale Rack

Biologics are the fastest-growing class of therapeutic products in the United States. As products of genetic engineering technology, they were initially introduced in the 1980s and the segment has been…

0 Comments

Biologics from China

Reported on 8 March by Eric Palmer from Fierce Pharma, 2018 marks a landmark event in the global biologics supply chain—for the first time, an FDA approved biologic will be…

0 Comments
Antibodies to watch in 2018
Monoclonal antibody (mAb or moAb), made by identical immune cells that are all clones of a unique parent cell. Most biotech drugs are monoclonal antibodies

Antibodies to watch in 2018

We have reported before on the annual preview of mAb products published by the journal mAbs at the start of each new year. For 2018, Hélène Kaplon & Janice M.…

0 Comments

More fun with bispecific antibodies!

The eagerly awaited Part 2 of our review of bispecific antibodies (bsAbs) entitled “Therapeutic IgG-Like Bispecific Antibodies-Modular Versatility and Manufacturing” appears in the January 2018 issue of BioProcess International. In…

0 Comments
Close Menu